Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Zeno Alpha Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04514159
- Locations
- 🇺🇸
Site 1, Charleston, South Carolina, United States
🇵🇱Site 4, Kraków, Poland
🇵🇱Site 5, Łódź, Poland
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC V8Anatomic Stage IA Breast Cancer AJCC V8Anatomic Stage IB Breast Cancer AJCC V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage IIA Breast Cancer AJCC V8Anatomic Stage IIB Breast Cancer AJCC V8Anatomic Stage IIIA Breast Cancer AJCC V8HER2 Negative Breast AdenocarcinomaHormone Receptor Positive Breast AdenocarcinomaInvasive Breast Carcinoma
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT04481113
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04469764
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT04408924
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇫🇷Hopital Europeen Georges Pompidou, Paris, France
🇺🇸University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
Abemaciclib and Letrozole to Treat Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 53
- Registration Number
- NCT04393285
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸University of Miami - Sylvester Cancer Center, Miami, Florida, United States
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 50
- Registration Number
- NCT04391595
- Locations
- 🇺🇸
HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States
🇺🇸Chandler Regional Medical Center, Chandler, Arizona, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Duke University
- Target Recruit Count
- 18
- Registration Number
- NCT04352777
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Academic and Community Cancer Research United
- Registration Number
- NCT04351230
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT04316169
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.